Share on StockTwits

Analysts at BNP Paribas raised their price objective on shares of Smith & Nephew plc (LON:SN) from GBX 1,000 ($17.02) to GBX 1,250 ($21.27) in a research report issued to clients and investors on Wednesday. The firm currently has an “outperform” rating on the stock. BNP Paribas’ price target indicates a potential upside of 21.23% from the company’s current price.

Smith & Nephew plc (LON:SN) traded down 1.33% on Wednesday, hitting GBX 1031.10. 3,102,332 shares of the company’s stock traded hands. Smith & Nephew plc has a one year low of GBX 720.00 and a one year high of GBX 1136.00. The stock’s 50-day moving average is GBX 1002. and its 200-day moving average is GBX 924.6. The company’s market cap is £9.208 billion.

Several other analysts have also recently commented on the stock. Analysts at Goldman Sachs reiterated a “neutral” rating on shares of Smith & Nephew plc in a research note on Tuesday. They now have a GBX 1,070 ($18.21) price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew plc in a research note on Wednesday, June 18th. They now have a GBX 1,160 ($19.74) price target on the stock. Finally, analysts at Galvan Research reiterated a “buy” rating on shares of Smith & Nephew plc in a research note on Wednesday, June 11th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of GBX 959.63 ($16.33).

Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.